Nyxoah Initiates Search for US-Based CEO to Accelerate Genio Launch
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
Tag: Nyxoah
All
Latest
All
Latest
Nyxoah’s Genio Neurostimulator for OSA Launches in England
The launch is marked by the first successful patient implants at University College London Hospitals.
All
Latest
One Less Worry About Neurostimulators
The past year has brought relief that one bump in the pathway to neurostimulator use has been smoothed down for sleep apnea patients.
Nyxoah Prepares Final FDA Premarket Approval Module for Genio OSA Neurostimulator
Nyxoah advances its US launch plans for the Genio system, which recently achieved positive co-primary endpoints in the DREAM US pivotal study.
Read More
Neurostimulator Offers Relief to Young Man with Down Syndrome and OSA
Nick Lopez, 20, found relief from OSA after receiving Inspire therapy, now FDA-approved for Down syndrome patients as young as 13. Other neurostimulators are in the pipeline.
Read More
Nyxoah Appoints Hypoglossal Nerve Stimulation Pioneer as CMO
The new CMO brings surgical and academic expertise in hypoglossal nerve stimulation.
Read More
Nyxoah Teams Up With AAO-HNSF to Enhance Access to New Sleep Apnea Treatments
The partnership seeks improve patient access to new sleep apnea treatments by streamlining authorization pathways and advocating for broader access to neurostimulator therapies.
Read More
Genio Neurostimulator Reduces Sleep Apnea Severity in Nyxoah’s DREAM US Study
Nyxoah announced 12-month results from its DREAM US pivotal study, designed to support the marketing authorization of the Genio hypoglossal nerve stimulation system for obstructive sleep apnea in the United States.
Read More
Nyxoah to Unveil OSA Neurostimulation Study Results by Early April
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea.
Read More
Nyxoah Sets Key Milestones for 2024, Aims to Replicate Its European Success Stateside
Nyxoah’s CEO says the company is on the cusp of “the most significant milestone” in its history.
Read More
Nyxoah’s Preliminary Data Shows Revenue Surge Due to Genio Demand for OSA
Nyxoah says the anticipated growth reflects both strong underlying demand for Genio and a focus on streamlining the patient referral pathway.
Read More
Genio Neurostimulator Improves Sleep Apnea in Three Complete Concentric Collapse Patients
In a real-world case series, the Genio neurostimulator effectively reduced sleep apnea symptoms in patients with complete concentric collapse, demonstrating significant improvements in AHI and sleepiness.
Read More
Nyxoah Advances Genio Neurostimulator for OSA in Q3
Nyxoah SA reported a successful third quarter with clinical trial progress for its Genio neurostimulator system for the treatment of obstructive sleep apnea.
Read More
Nyxoah and ResMed Germany Unite for Comprehensive Sleep Apnea Care
Nyxoah SA has partnered with ResMed Germany to increase OSA awareness and therapy penetration in the German market.
Read More
Nyxoah Speeds Pre-Commercialization as Neurostimulator Trial Progresses
Nyxoah announced operating results for the second quarter and first half of 2023, emphasizing advances in its investigational device exemption trial designed to support the marketing authorization of the Genio neurostimulator system for the treatment of OSA.
Read More
Nyxoah Highlights Positive Early Findings from Neurostimulator Trial for Sleep Apnea
The company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
Read More
Nyxoah Progresses in Neurostimulator Studies for Sleep Apnea
The clinical and regulatory milestones bring Nyxoah closer to offering its Genio neurostimulator solution to OSA patients in the US, according to the company.
Read MoreFDA Approves Nyxoah Genio 2.1 For Use in DREAM Pivotal Study for Obstructive Sleep Apnea
Genio 2.1’s upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.
Read More